Reported 27 days ago
Despite recent sell-offs, Viking Therapeutics and Recursion Pharmaceuticals present intriguing investment opportunities due to their innovative approaches in weight loss and drug development, respectively. Viking's promising candidate for obesity treatment and its potential asset for metabolic disorders could lead to a substantial market presence, while Recursion aims to revolutionize drug development via AI technology. However, both stocks carry considerable risk, and investors should proceed with caution.
Source: YAHOO